KYOWA Hakko Kirin International, the Galashiels-headquartered life sciences company formerly called ProStrakan, has hailed a significant milestone in its bid to commercialise an antibody for the treatment of a rare bone disease in children and adolescents, X-linked hypophosphatemia (XLH).

The conditional approval of burosumab, by the European Medicine Agency, marks the first regulatory breakthrough for a pipeline products from KKI’s parent company, Tokyo-based Kyowa Hakko.